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Abstract
Determination of viral characteristics including genotype (GT), subtype 
(ST) and resistance-associated variants (RAVs) profile is important in assigning 
direct-acting antivirals regimes in HCV patients. To help achieve the best clini-
cal management of HCV patients, a routine diagnostic laboratory should aim at 
reporting accurate viral GT/ST and RAVs using a reliable diagnostic platform of 
choice. A laboratory study was conducted to evaluate performance characteristics 
of a new commercial next-generation sequencing (NGS)-based HCV genotyping 
assay in comparison to another widely used commercial line probe assay for HCV 
genotyping. Information on RAVs from deeply sequenced NS3, NS5A and NS5B 
regions in samples classified as HCV 1a and 1b was harnessed from the fully auto-
mated software. Perfect (100%) concordance at HCV genotype level was achieved 
in GT2 (N = 13), GT3 (N = 55) and GT5 (N = 7). NGS refined the ST assignment in 
GTs 1, 4 and 6, and resolved previously indeterminate GTs reported by line probe 
assay. NGS was found to have consistent intra- and inter-run reproducibility in 
terms of genotyping, subtyping and RAVs identification. Detection of infections 
with multiple HCV GTs or STs is feasible by NGS. Deep sequencing allows sensitive 
identification of RAVs in the GT 1a and 1b NS3, NS5A and NS5B regions, but the list 
of target RAVs is not exhaustive.
Keywords: resistance-associated variants, next-generation sequencing,  
hepatitis C, HCV genotyping, NGS
1. Introduction
Due to the genetic diversity of the hepatitis C virus (HCV), its accurate genotyp-
ing is still currently challenging despite the use of modern molecular techniques. In 
addition to the six widely-recognised HCV genotypes, a newly identified genotype 
(GT) 7 was reported in 2015 [1]. Molecular methods including reverse hybridization, 
real-time PCR and Sanger sequencing are commonly utilised for HCV genotyping and 
subtyping in clinical laboratories. HCV genotype and subtype (ST) have been the crit-
ical factors in decision-making for administering interferon-based therapies for the 
past decade [2]. According to the latest AASLD guidelines [3], determination of viral 
characteristics including GT, ST and resistance-associated variants (RAVs) profile is 
important in assigning direct-acting antivirals (DAAs) regimes in HCV patients.
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To help achieve the best clinical management of HCV patients, a routine diag-
nostic laboratory should aim at minimising reporting out non-informative HCV 
genotyping results which are due to inherent limitations of the diagnostic platform 
of choice. In general, about 2–8.5% of HCV positive samples have been reported to 
carry “indeterminate” GTs by several commercial assays [4–9]. To tackle uncertain-
ties in determining HCV GT and ST, Sanger sequencing could be utilised to resolve 
indeterminate or discordant GTs or ST results produced by commercial assays 
[10, 11]. Despite the ability to provide definitive genotyping information most of 
the time, unfavourable features of Sanger sequencing including low throughput, 
time-consuming procedures and relatively high costs, pose a barrier to it becoming 
routinely adopted as a first-line genotyping method. With the advent of next-gener-
ation sequencing (NGS), limitations of probe-based genotyping assays and Sanger 
sequencing for HCV genotyping can be overcome. NGS provides a high-resolution 
means for direct sequence-based interrogation of the HCV genome. Moreover, NGS 
also allows concurrent profiling of RAVs where such value-added feature is highly 
relevant for the clinical management of HCV infection with appropriate use of DAAs.
In the present study, the Sentosa SQ HCV genotyping assay (hereinafter referred 
to as Vela NGS) (Vela Diagnostics, Singapore) which primarily interrogates the 
NS5B region of HCV GTs 1–6 by ion torrent-based NGS technology, was evaluated 
in comparison to the VERSANT HCV Genotype 2.0 Assay (hereinafter referred 
to as LiPA) (Siemens Healthineers, Erlangen, Germany). HCV indeterminate GTs 
previously reported in clinical samples by LiPA were resolved using Vela NGS assay 
with further confirmation by Sanger sequencing. Information on RAVs was also 
harnessed from deeply sequenced NS3, NS5A and NS5B regions in samples classi-
fied as HCV 1a and 1b using Vela NGS.
2. Study design
2.1 Clinical samples
This study was performed on residual sera or plasma from 222 clinical specimens 
previously received for routine genotyping using the VERSANT HCV Genotype 2.0 
Line Probe Assay (Siemens Healthineers, Erlangen, Germany). All samples were stored 
at -80°C post-LiPA analysis and were only thawed prior to re-analysis by NGS and 
Sanger sequencing. All samples were de-identified for anonymisation purposes, and 
hence, the treatment histories remain unknown and cannot be traced. These were all 
residual samples, which would otherwise be discarded, and were used for the purposes 
of assay validation only. In such situations, ethics approval is not normally required, as 
all samples could not be linked back to the original patients after anonymisation.
2.2 NGS by Sentosa SQ HCV genotyping assay
In this study, NGS was performed using Sentosa SQ HCV Genotyping Assay 
(4 × 16) (Vela Diagnostics, Singapore) according to the manufacturer’s instruc-
tions. The workflow started with automated extraction of total nucleic acids from 
530 μL of sera or plasma using Sentosa SX Virus Total Nucleic Acid Plus II kit (Vela 
Diagnostics) on Sentosa SX101 (Vela Diagnostics). PCR amplification of the HCV 
NS3, NS5A and NS5B regions was performed on Veriti 96-Well Thermal Cycler 
(Applied Biosystems, CA, USA). In every individual run, a pooled library containing 
barcoded amplicons of 15 clinical samples and one system control, was prepared by 
Sentosa SX101. The pooled library was subject to sequencing template preparation 
and enrichment on Sentosa ST401 (Vela Diagnostics). Sequencing data generated 
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by Sentosa SQ301 (Vela Diagnostics) was automatically channelled for primary 
and subsequent secondary analyses using Sentosa SQ Suite (Vela Diagnostics) and 
Sentosa SQ Reporter (Vela Diagnostics), respectively. Auto-generated quality con-
trol and pathology reports containing technical information, viral typing, and RAVs 
(available only for GTs 1a and 1b) results were manually reviewed, respectively.
2.3 VERSANT HCV Genotype 2.0 Line Probe Assay
Total nucleic acids were extracted from 200 μL sera or plasma using EZ1 Virus 
Mini Kit v2.0 (QIAGEN, Hilden, Germany) on Biorobot EZ1 (QIAGEN). Using 
VERSANT HCV Genotype 2.0 Line Probe Assay (LiPA) (Siemens Healthineers), a 
one-step reverse transcription-polymerase chain reaction (RT-PCR) amplifying the 
5’UTR and core regions was performed on GeneAmp PCR System 9700 (Applied 
Biosystems). Reverse hybridisation, washing and colour development steps were 
performed on Autoblot 3000H (Fujirebio Europe, Gent, Belgium). For GT and ST 
determination, band patterns were manually scored by aligning the strips to an 
interpretation chart provided by the manufacturer.
2.4 Sanger sequencing
Sanger sequencing was performed on samples previously reported by LiPA as 
indeterminate genotype. A primary PCR amplification of a 454 bp fragment of the 
NS5B region was initially attempted using primers 5Bo8254 and 5Bo8707 [12]. In 
samples with PCR failure using the above-mentioned primers, a secondary PCR 
amplifying a 446 bp fragment of the 5’UTR/core regions was subsequently per-
formed using primers UTR45 and Cor490 [12]. PCR products from the amplifiable 
gene segments were subjected to direct sequencing with BigDye Terminator v3.1 
Cycle Sequencing kit (Applied Biosystems) using the respective PCR primers on a 
3130XL Genetic Analyzer (Applied Biosystems).
2.5 Sequence analysis
Sequence analysis was performed by querying the nucleotide sequences obtained 
from Sanger sequencing in the Los Alamos hepatitis C sequence database [13]. For Vela 
NGS, assembled contigs were downloaded from the Sentosa SQ Reporter software. In 
samples with discordant results between LiPA and Vela NGS, NGS contigs were uploaded 
to the Los Alamos hepatitis C sequence database [13] to verify Vela NGS results.
3. Results
3.1  Concordance between results generated by the Vela NGS and Versant 
platforms at GT and ST levels
The Vela NGS results at both GT and ST levels were tabulated in Table 1 for 
170 clinical samples with GT and/or ST results from LiPA. Perfect (100%) con-
cordance at HCV genotype level was achieved in GT 2 (N = 13), GT 3 (N = 55) and 
GT 5 (N = 7). For samples reported by LiPA as GT 1 (N = 40), 20% (N = 8) gave 
discrepant results when compared to Vela NGS. These samples had been previ-
ously classified by LiPA as either GT 1a with core inconclusive, GT 1b with 96.1% 
homology, GT 1b with core inconclusive, or GT 1b with core not available, due to 
their unconventional band patterns. There was no discrepancy between samples 
firmly reported as GT 1a and GT 1b by LiPA. In samples reported as GT 4 (N = 16) 
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by LiPA, 43.8% (N = 7) were found to be GT 3 by Vela NGS. Two samples (5.1%) 
originally reported by LiPA as GT 3 were classified by Vela NGS as GT 6 samples.
At ST level, Vela NGS reclassified 1 sample previously assigned as HCV 1a with 
core inconclusive by LiPA as 1c. Two samples each reported as 4a/4c/4d and 4e by 
LiPA, respectively, were reclassified as 4n and 4o by Vela NGS. Another 29 GT 6 
(ST c-l) samples reported by LiPA were reassigned by Vela NGS as 6e/6u (N = 1), 
6j (N = 1), 6m (N = 9), and 6n (N = 18), respectively. One sample with LiPA 6m 
(77.9% homology) was reassigned as 6u by Vela NGS.
3.2  Verification of contig sequences generated by the Vela NGS in samples with 
discordant results
Of the 170 samples tested, there were 104 agreements at both GT and ST levels, 
49 partial agreements at genotype but not the subtype levels, and 117 discordant 
results generated by LiPA and Vela NGS (Table 1). At GT level, the calculated 
Cohen’s Kappa is 0.869 (95% confidence interval: 0.810–0.928), suggesting good 
strength of agreement between the two assays. The 66 NGS contig sequences of 
samples with partial agreement or discordant results were submitted to the online 
analysis in the Los Alamos hepatitis C sequence database. HCV GT and ST called by 
Vela NGS were verified in all 66 contigs.
3.3  Intra-run and inter-run reproducibility on GT and ST calling by Vela NGS
HCV genotyping and subtyping results were found to be reproducible for a panel 
of 5 samples with different HCV GT/ST including 1a, 1b, 2a, 3a and 3b tested in 
triplicates within a single run on the Vela NGS platform (Figure 1a). For inter-run 
reproducibility testing (Figure 1b), GT and ST results were consistently reported in 
another panel of 7 samples including 1a, 1b, 2b, 3a, 4d, 5a and 6n, which were repeat-
edly tested in three separate runs on different days. Details of viral load and median 
coverage of the targeted NS5B region are depicted in Figure 1a and b, respectively.
3.4 RAV analysis in GT 1 samples reported by the Vela NGS platform
In the current Vela NGS assay, a list of variants differing from the wild-type codons 
are detectable for HCV 1a and 1b. The 16 target codons in the NS3 gene are 36, 41, 43, 54, 
55, 80, 109, 122, 132 (1a only), 138, 155, 156, 158, 168, 170 (1b only) and 175 (1b only). 
For NS5A, variants at nine codons including 28 (1a only), 30 (1a only), 31, 32, 54 (1b 
only), 58, 62 (1b only), 92 and 93, are detectable. Eight codons in the NS5B gene includ-
ing 414, 419, 422, 423, 495, 499 (1b only), 554 and 559, are also covered in this assay.
Of 13 GT 1a samples (Table 2), five were found to carry at least one target variant 
in the NS3 gene. Notably, two samples carried the Q80K RAV. For NS5A, the M28A 
variant was detected in one sample in which NS3 Q80K was also present. None of the 
GT 1a samples was found to carry any of target variants in the NS5B gene.
Of 18 HCV 1b samples (Table 2), five were detected with at least one target vari-
ant in the NS3 gene. Twelve samples were identified with at least one target variant 
in the NS5A gene. For NS5B, the P495A and V499A variants were detected in one 
and eight samples, respectively. Notably, there were four samples detected with at 
least one target variant in each of the NS3, NS5A and NS5B genes.
3.5 Intra-run and inter-run reproducibility on variant calling and frequency
In intra-run reproducibility analysis, the Q80K variant was reproducibly 
detected in the NS3 gene of the GT 1a samples. Another two variants, namely Q54H 
5HCV Genotyping with Concurrent Profiling of Resistance-Associated Variants by NGS Analysis
DOI: http://dx.doi.org/10.5772/intechopen.84577
T
ab
le
 1
. 
C
om
p
ar
is
on
 o
f 
G
T
 a
n
d
 S
T
 d
is
tr
ib
u
ti
on
 i
n
 1
70
 s
am
p
le
s 
te
st
ed
 b
y 
b
ot
h
 L
iP
A
 a
n
d
 V
el
a
 N
G
S
.
Bioinformatics Tools for Detection and Clinical Interpretation of Genomic Variations
6
Figure 1. 
Precision studies on the Vela NGS. (a) Intra-run and (b) inter-run reproducibility on median read depth 
were tested on 5 and 7 clinical specimens, respectively. For RAV analysis, variants were called with reproducible 
frequency (c) within a run (intra-run) and (d) between runs (inter-run).
No ID GT1 
STs
RAVs (variant frequency)
NS3 NS5A NS5B
1 R02-BC02 1a S122G (99.21%), D168E 
(97.07%)
– –
2 R02-BC03 1a V55A (91.44%) – –
3 R02-BC04 1a Q80K (25.63%) M28V (99.47%) –
4 R02-BC05 1a Q80K (4.84%) – –
5 R13-BC13 1a D168E (51.43%) – –
6 R01-BC02 1b Q80K (55.29%)
M175L (87.81%)
– V499A (98.15%)
7 R01-BC03 1b – – V499A (97.03%)
8 R01-BC04 1b – L31M (22.03%), Q54H 
(98.82%)
V499A (33.65%)
9 R01-BC05 1b – Q54H (99.11%), Y93H 
(99.73%)
–
10 R01-BC06 1b Q80L (99.52%), S122G 
(9.99%)
Q54H (99.05%) V499A (97.91%)
11 R01-BC07 1b – Q54H (98.76%), Y93H 
(99.61%)
–
12 R01-BC08 1b – Q54H (99.22%), Q62E 
(99.04%)
–
13 R01-BC09 1b S122G (97.69%) Q54H (99.21%), Q62E 
(51.64%)
P495A 8.83%
14 R01-BC11 1b – Y93H (99.24%) –
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No ID GT1 
STs
RAVs (variant frequency)
NS3 NS5A NS5B
15 R02-BC07 1b – Q54H (99.37%) V499A 98.9%
16 R02-BC-11 1b Q80R (92.29%) Q62E (5.61%) V499A 95.15%
17 R11-BC14 1b M175L (99.97%) Y93H (99.8%) V499A 98.7%
18 R12-BC14 1b – Q54H (80.35%), Y93H 
(8.07%)
–
19 R12-BC15 1b – Q54H (98.82%), Q62R 
(99.79%)
–
In this study, RAVs with variant frequency less than 1% are not shown.
Table 2. 
List of resistance-associated variants (RAVs) identified in GT 1a and 1b samples by Vela NGS.
No LiPA results (bands) Vela 
NGS
Sanger sequencing Concordance at 
GT or ST level
NS5B 5‘UTR/core
1 Indeterminate (3,6,16,24) 6n Not amplified 6n GT & ST
2 Indeterminate (3,6,16,24) 6n Not amplified 6n GT & ST
3 Indeterminate (3,6,16,24) 6n Not amplified 6n GT & ST
4 Indeterminate (6,7,24) 3b 3b Not done GT & ST
5 Indeterminate (6,7,24) 6m/6u Not amplified 6e/6d GT only
6 Indeterminate (6,7) 6u 6u/6n Not done GT & ST
7 Indeterminate (6,7) 6u 6m/6n Not done GT only
8 Indeterminate (6,7) 6u 6n/6a Not done GT only
9 Indeterminate (6) 6m/6l 6d/6e Not done GT only
10 Indeterminate (17,24) 3b 3b Not done GT & ST
11 Indeterminate (17,18,24) 3b 3b Not done GT & ST
12 Indeterminate (6,17,24) 3b 3b Not done GT & ST
13 Indeterminate (7,8,14,15,24) 3a 3a Not done GT & ST
14 Indeterminate (7,13,17,18) 3b 3b Not done GT & ST
15 Indeterminate (7,13,17,18,24) 3b 3b Not done GT & ST
16 Indeterminate (13,16,17,18,24) 3b 3b Not done GT & ST
17 Indeterminate (13,14,15,18,24) 3b 3b Not done GT & ST
18 Indeterminate (3,4,13,25) 1a 1a Not done GT & ST
19 Indeterminate (3,4,7,13,25) 1a 1a Not done GT & ST
20 Indeterminate (3,4,7,13,24) 6e 6e Not done GT & ST
21 Indeterminate (3,4,6,7,13,24) 6e Not amplified 6e/6d GT & ST
22 Indeterminate (5,9,21,24) 6a Not amplified 6a GT & ST
23 Indeterminate (5,6,9,17,18) 4a Not amplified 4a GT & ST
24 Indeterminate (5,9,10,13,14,15,24) 2a & 
3a
Two mixed 
sequences
Not done Likely mixed 
infections
25 Indeterminate (5,8,9,11) 2a 2a Not done GT & ST
26 Indeterminate (24) 3b 3b Not done GT & ST
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and V499A were also repeatedly identified in the NS5A and NS5B genes of the GT 1b 
sample, respectively. Variant frequencies of the three variants were highly repro-
ducible within run (Figure 1c).
In the inter-run reproducibility study, NS3 S122G and NS5B V499A variants were 
tested. Variant frequencies of the two variants were found to be highly reproducible 
among the three separate runs (Figure 1d).
3.6  Vela NGS assigned HCV GT and ST to samples with indeterminate  
LiPA results
Forty specimens, which were previously reported as HCV indeterminate GT by 
LiPA, were subject to Vela NGS analysis. Sanger sequencing were successfully per-
formed on NS5b (N = 30) or 5’UTR/core (N = 10) regions in 40 samples (Table 3). 
Of the 40 samples with Sanger sequencing results, Vela NGS results were confirmed 
at GT level in 39 samples (97.5%). In a sample with LiPA complex band patterns (5, 
9, 10, 13, 14, 15 & 24), a mixed genotypes of GT 2a and GT 3a were assigned by Vela 
NGS. Sanger sequencing on NS5B showed overlapping nucleotide base calls in the 
overall sequences, in which putative mixed infection with two different HCV GTs 
was likely inferred.
4. Discussion
The application of NGS assays to analyse quasispecies HCV genomes has been 
increasing in recent years. Several laboratory-developed NGS assays had been 
No LiPA results (bands) Vela 
NGS
Sanger sequencing Concordance at 
GT or ST level
NS5B 5‘UTR/core
27 Indeterminate (24) 3b 3b Not done GT & ST
28 Indeterminate (4,5,9,16,21,24) 6a 6a Not done GT & ST
29 Indeterminate (4,9,21) 6a Not amplified 6a GT & ST
30 Indeterminate 
(3,4,6,13,17,18,24,26)
3b 3b Not done GT & ST
31 Indeterminate (6) 6n/6a 6d/6u Not done GT only
32 Indeterminate (3,4,13,25) 1a 1a Not done GT & ST
33 Indeterminate (6) 6u 6u Not done GT & ST
34 Indeterminate (13,16,24) 3b 3b Not done GT & ST
35 Indeterminate (7) 6u Not amplified 6v/6l/6d/6k GT only
36 Indeterminate (17,18,24) 3b 3b Not done GT & ST
37 Indeterminate (3,4,5,16,25) 1a Not amplified 1a GT & ST
38 Indeterminate (5,6,18,24) 3k 3k Not done GT & ST
39 Indeterminate (8,9,21,24) 6a 6a Not done GT & ST
40 Indeterminate (3,4,6,16,24) 6q 6q Not done GT & ST
PCR amplification for NS5B was first attempted in all 40 specimens. A secondary PCR amplifying 5'UTR/core 
regions were performed in samples with unsuccessful amplification of NS5B. Sanger sequencing was performed on 
PCR amplicon obtained.
Table 3. 
Comparison of genotyping results produced by the Vela NGS and Sanger sequencing methods in 40 specimens 
with indeterminate genotypes by LiPA.
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previously described in the literature for phylogenetic studies [14], outbreak inves-
tigation [15, 16], characterisation of HCV full genome [17, 18] and identification 
of HCV GT and ST in clinical samples [19, 20]. However, there are fewer reports 
of adoption of NGS assays in routine HCV genotyping. In 2016, Vela NGS became 
available as a CE-IVD certified commercial kit for diagnostic use in the clinical 
laboratories. In this study, we report the performance characteristics of Vela NGS in 
comparison to the widely used LiPA assay for HCV genotyping.
The performance of Vela NGS in determining the HCV GT and ST in the clinical 
specimens had been discussed in several previous studies [21–23]. Perfect agree-
ment at GT level was observed between Vela NGS and LiPA in a study by Manee 
et al. [21]. Samples with unclear ST results in GTs 2, 3, 4 and 6 reported by LiPA 
were each assigned with a specific subtype after subject to Vela NGS analysis. Dirani 
et al. [22] also performed a direct comparison of GT and ST calling between Vela 
NGS and LiPA for samples from patients infected with HCV GTs including GT 1, 2, 
3 and 4, and found a high concordance (>99%) at GT level between the two tests. 
Vela NGS was also found to have better performance in assigning HCV STs among 
the four GTs when compared to LiPA [22]. In another study by Rodriguez et al. [23], 
Vela NGS achieved high concordance rates with Sanger sequencing in assigning GTs 
1 to 6, 1a and 1b STs, and other STs for GTs 4, 5 and 6. Discrepant calls at ST level 
was mainly found among HCV GTs 1 and 2 between Vela NGS and Sanger sequenc-
ing; the latter was used as the reference method to sequence the 286 bp segment of 
NS5B for which phylogenetic analysis was performed.
In the present study, discrepancy in results was mainly observed in samples with 
LiPA GT 1b with incomplete or missing bands at the core region. In this particular 
result group, GT 6 with different STs were assigned by Vela NGS. This observation 
was not unexpected as it has been specified in the LiPA interpretation chart that GT 
6 (STs c-1) cannot be differentiated from ST 1a and 1b without additional informa-
tion from the core region sequence. Among LiPA GT 4 samples, all ST 4h were 
reassigned as GT 3 by Vela NGS. Some geographical regions, for example, Southeast 
Asia, where GT 6 is highly prevalent [24], could thus be impacted more by this mis-
classification with the use of LiPA method.
In contrast to LiPA which utilises primarily the 5’UTR in GTs 1-6 and core regions 
for the discrimination of GT 6 STs c-l from 1a and 1b, Vela NGS targets the non-
structural genes implicated in both accurate genotyping/subtyping and resistance to 
DAAs. The LiPA is known to be poor at detecting and identifying recombinant forms 
of HCV [25]. Due to the assay design of Vela NGS, this may also pose a problem for 
this platform, despite the application of NGS technology. The HCV recombinant 
forms can be accurately detected via sequencing of recombination breakpoint 
junctions or the whole HCV genome [26]. For example, in our study, one previously 
LiPA-indeterminate sample was reported by the Vela NGS to have mixed HCV infec-
tions with HCV 2a and 3a. This NGS finding was confirmed by Sanger sequencing in 
which overlapping Sanger electropherograms were observed for NS5B.
The Vela NGS offers information on RAVs in HCV 1a or 1b positive samples, 
where such profiling will be useful when prescribing DAA regimes, and detecting 
of baseline or emerging RAVs. Targeted assays had been previously developed to 
identify a specific RAV [27, 28]. RAVs which are found at levels with at least 15% 
variant frequency, at baseline, are known to confer resistance to certain DAAs [29], 
and therefore may impact on the effectiveness of DAA treatment [30]. Vela NGS tar-
gets relevant RAVs in three non-structural gene segments (NS3, NS5A and NS5B) of 
HCV 1a and 1b, and although the RAV profiling is comprehensive but not exhaustive 
due to the assay design, any baseline RAVs present in any of these DAA target genes, 
can affect the therapeutic effectiveness [31]. In our study, four HCV 1b samples were 
found to harbour variants in all three NS3, NS5A and NS5B genes concurrently.
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5. Conclusions
In conclusion, the genotyping results of the Vela NGS were found to be highly 
concordant with those of the LiPA method. Vela NGS refined the ST assignment in 
GT 6 and resolved previously indeterminate GTs reported by LiPA. Technically, the 
HCV Vela NGS was found to have consistent intra- and inter-run reproducibility in 
terms of GT and ST calling and RAVs identification. Detection of infections with 
multiple HCV GTs or STs is feasible by Vela NGS. Due to the assay design which 
relies on investigating the HCV sub-genomic regions, HCV recombinant strains 
may still be potentially missed. Deep sequencing allows sensitive identification of 
RAVs in the GT1a and 1b NS3, NS5A and NS5B regions, but the list of target RAVs 
is not exhaustive. We would also suggest the RAVs detection spectrum should be 
extended to cover GTs other than HCV 1a and 1b, namely GTs 2-6.
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